Scholar Rock Holding Corp (fra:2QK) Share Price

Company Profile

Business description
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Contact
301 Binney Street
3rd Floor
CambridgeMA02142
USA
T: +1 857 259-3860
E: [email protected]
https://www.scholarrock.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
289

Recommended

High debt levels and low commodity prices were a concern, but agreed sell-downs and a ramp-up of key operations should help.

Mark Taylor | 21 April 2026

John Ternus, Apple’s hardware chief, will take up the role in September.

William Kerwin, CFA | 21 April 2026

Our view as China’s steel production drops.

Jon Mills, CFA | 21 April 2026

Index	Last price	Change	% Change
All Ordinaries	9,074.40	50.80	-0.56%
CAC 40	8,156.43	79.28	-0.96%
DAX 40	24,194.90	75.97	-0.31%
Dow JONES (US)	49,430.45	281.07	0.57%
FTSE 100	10,476.46	21.63	-0.21%
HKSE	26,163.24	324.24	-1.22%
NASDAQ	24,595.47	335.51	1.38%
Nikkei 225	59,585.86	236.69	0.40%
NZX 50 Index	12,945.60	13.27	0.10%
S&P 500	7,124.57	60.56	0.86%
S&P/ASX 200	8,843.60	53.20	-0.60%
SSE Composite Index	4,106.26	21.18	0.52%